BioSenic Company Description

BioSenic S.A., a biotech company, focuses on developing clinical assets.

Its technologies include cutting-edge allogeneic cell and gene therapy platform with differentiated bone marrow sourced mesenchymal stromal cells, which can be stored at the point of use in the hospital; and Arsenic TriOxide platform for use in immuno-oncology to treat graft-versus-host disease, systemic lupus erythematosus, and systemic sclerosis.

The company’s investigational medicinal product is ALLOB, which is in a Phase IIb clinical trial in patients with difficult tibial fractures’ and ArsciCor, which is in Phase III in GvHD is being prepared with an oral treatment.

BioSenic S.A. is based in Mont-Saint-Guibert, Belgium.

BioSenic S.A.

Country	Belgium
Industry	Biotechnology
Sector	Healthcare

Contact Details

Address: Building H (box 24) Mont-Saint-Guibert, 1435 Belgium
Phone	32 493 09 73 66
Website	biosenic.com

Stock Details

Ticker Symbol	0R55
Exchange	London Stock Exchange
Fiscal Year	January - December
Reporting Currency	EUR
ISIN Number	BE0974280126
SIC Code	2836

Key Executives

Name	Position
Dr. Miguel Forte M.D., Ph.D.	Chief Executive Officer, MD and Executive Director
Dr. Anne-Sophie Lebrun Ph.D.	Chief Operations Officer
Dr. Anthony Ting Ph.D.	Chief Scientific Officer
Gunther De Backer	Head of Corporate Communications and Investor Relations
Valerie Chapelle	Interim Human Resources Director
Dr. Stefanos Theoharis Ph.D.	Chief Business Officer
Dr. Anne Leselbaum M.D.	Chief Medical Officer
Ching Man Choi	Business Development Manager